On November 15 & 16, 2017 was the 2nd annual Drug Pricing Policy Summit in Toronto, Ontario. Varied patient groups joined the Canadian Cancer Survivor Network, Schizophrenia Society of Ontario, and Save Your Skin Foundation to discuss: Drug Pricing Policy in Canada: Measuring Progress and Making Our Mark
This year’s Summit built on the inaugural 2016 Summit with updates from across the regulatory, public and private policy environments. In addition, the 2017 Summit presented different views on drug pricing policy in Canada, including perspectives on value-based healthcare with a focus on patient outcomes and putting the patient at the centre of the process. Panelists included leaders in the public and private payer environments, pharmaceutical industry and prescribers.
To read more about the background information, visit the Canadian Cancer Survivor Network website for the following link and more: Click here to view a description of bodies involved in drug pricing policy in Canada.
To learn more about the DPPS Working Groups or to inquire about getting involved in them, please email: DPPSWorkingGroups@gmail.com
Updated December 19, 2017:
We are proud to share the reports from the 2017 Summit, in English and in French. Please click on images below to read the reports:
Recordings of the sessions that occurred over the two days are also available via youTube, to view the collection please click here.
**********************************************************************************************************************
The following webinars were presented prior to this year’s Summit, detailing updates on the climate of drug pricing policy in Canada.
October 18, 2017, pan-Canadian Public Health Systems : The Basics
Presenters: Wayne Critchley, Louise Binder
Please click here to watch the recording of this webinar
This webinar will provide a broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada, describing the legal framework, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement. This is a primer for attendees attending the November 15-16, 2017 Drug Pricing Policy Summit and for others who would like to have a review of these systems for their interest.
November 1, 2017, Health Technology Assessment : What does value really mean for public drug plans?
Presenter: Matthew Brougham
Please click here to watch a recording of this webinar
This webinar will describe the process used by nine provinces and the territories to assess the value of a drug in determining whether public drugs plans should reimburse the drug through their plans. This is called a health technology assessment. It will describe the role and methodology of the Canadian Agency for Drugs and Technologies in Health in leading this assessment for both oncology and non-oncology drugs.
